Stocks see a familiar spike
Cannabis stocks enjoyed huge gains, which were seen after any mention of a rescheduling by White House officials. They corrected on Monday.
As per MEDCAN24′ Cannabis stock tracker shows that major US operators from multiple states saw explosive growth over the 10 day period, which included both Friday’s rally as well as Monday’s selloff. Terrascend soared by 69.62%. Curaleaf gained 57.94%. Cresco Labs grew 55.50%. Trulieve rose 53.73%.
Canadian licensed producers also followed the same pattern. Tilray Brands rose 53.75 % and Canopy Growth gained 35.34 % over the period. Cannabis ETFs have also seen dramatic changes. The AdvisorShares Pure US Cannabis ETF climbed 44.99% while the Amplify Seymour Cannabis ETF grew 46.32%.
No symbols available
This masks the intraday volatility. After the Washington Post’s and CNN’s initial reports, some stocks rose by over half in one session. After Trump was confirmed, by Monday the excitement had subsided. According to reports, major companies fell anywhere between 4%-13%. ReutersThe rally’s results were higher than expected.
His lukewarm Monday statement, describing cannabis as ‘a very complicated subject’ and noting ‘some people like it, some people hate it,’ provided little clarity on whether the administration will actually move forward or what form any action might take.
Trump, unlike former president Joe Biden who started the process by ordering his cabinet in 2020 to review cannabis schedules but did not order agencies to actually change them, could theoretically instruct Attorney General Pam Bondi directly to release a final ruling.
Legal experts say that the Controlled Substances Act grants the Attorney-General the power to reschedule a drug. Traditionally, this authority was delegated to DEA.
It would also bypass DEA administrator Terrance Cole, and the procedural tangles that stalled Biden’s efforts after they became bogged down by administrative hearings and improper communication between the DEA, anti-rescheduling group, and an interim appeal that halted the whole process in January 2025.
Even if Trump were to issue an executive directive, the DEA’s rule-making process could continue well past 2026, with the required review, comment, and hearing periods. It would be a convenient way for Trump to gain immediate political gains, such as 280E, but delay more burdensome regulatory obligations until after the midterm election.
The industry is still sceptical. Josh Kesselman of High Times said that although rescheduling is “a good start”, it does not represent meaningful reform. We fear that this could lead to the control of marijuana by large corporations and to more draconian cannabis laws, said Josh Kesselman, publisher of High Times.
Sasha Nutgent was optimistic. “As of today, with the classification as it is, retailers do not have an incentive to legally operate.” “Reclassification could change this for thousands of business.”
Stocks see a familiar spike
Cannabis stocks enjoyed huge gains, which were seen after any mention of a rescheduling by White House officials. They corrected on Monday.
As per MEDCAN24′ Cannabis stock tracker shows that major US operators from multiple states saw explosive growth over the 10 day period, which included both Friday’s rally as well as Monday’s selloff. Terrascend gained 69.62%. Curaleaf rose 57.94%. Cresco Labs grew 55.50%. Trulieve surged 53.73%.
Canadian licensed producers also followed the same pattern. Tilray Brands rose 53.75 % and Canopy Growth gained 35.34 % over the period. Cannabis-focused ETFs saw dramatic movements as well, including the AdvisorShares Pure US Cannabis ETF(MSOS), which rose 44.99%, and Amplify Seymour Cannabis ETF(CNBS), which climbed 46.32%.
No symbols available
This masks the intraday volatility. Stocks soared after the Washington Post and CNN reported on Friday. Some stocks gained over 50% within a single day. After Trump was confirmed, the excitement had subsided by Monday. According to reports, major companies fell anywhere between 4%-13%. ReutersThe rally’s results were higher than expected.
His lukewarm Monday statement, describing cannabis as ‘a very complicated subject’ and noting ‘some people like it, some people hate it,’ provided little clarity on whether the administration will actually move forward or what form any action might take.
Trump, unlike former president Joe Biden who started the process by ordering his cabinet in 2020 to review cannabis schedules but did not order agencies to reschedule it, could theoretically instruct Attorney General Pam Bondi directly to release a final ruling.
Legal experts say that the Controlled Substances Act grants the Attorney-General the power to reschedule a drug. Traditionally, this authority was delegated to DEA.
It would also bypass DEA administrator Terrance Cole, and the procedural tangles that stalled Biden’s efforts after they became bogged down by administrative hearings and improper communication between the DEA, anti-rescheduling group, and an interim appeal that halted the whole process in January 2025.
Even if Trump issued an executive order to that effect, the DEA’s rulemaking process with its required hearings, comment periods and reviews could extend well beyond 2026. This would allow for immediate gains in terms of 280E while delaying more intrusive regulatory requirements till after the midterm elections.
There is still widespread industry skepticism. Josh Kesselman is the publisher of High Times. He said that rescheduling was “a good start” but fell far short of real reform. We fear that this could lead to the control of marijuana by large corporations and further draconian law,” said Josh Kesselman, publisher of High Times.
Sasha Nutgent is the VP for Cannabis Retail of Housing Works Cannabis Co. She was more hopeful: “As things stand today with the existing classification, retailers aren’t incentivized by law to operate.” “Reclassification could change this for thousands of business.”
Cannabis Law Resources in Poland
Discover essential legal information about the cultivation of cannabis, its sale, and regulations governing medical products in Poland. These guides will help you understand the legal requirements, such as certification and permissions.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland